

A phase III randomised controlled trial of single-dose triple therapy: the IMPACT protocol

Steven J. Pascoe¹, David A. Lipson^{1,2}, Nicholas Locantore¹, Helen Barnacle³, Noushin Brealey³, Rajat Mohindra³, Mark T. Dransfield⁴, Ian Pavord⁵, Neil Barnes^{3, 6}

Affiliations: ¹Respiratory Research and Development, GSK, King of Prussia, PA, USA. ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US. ³Respiratory Medicines Development Centre, GSK, Brentford, UK. ⁴UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA. ⁵Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Oxford, UK. ⁶William Harvey Institute, Barts & The London School of Medicine and Dentistry, London, UK.

Correspondence: Steven J. Pascoe, Respiratory Research and Development, GSK, 709 Swedeland Road, King of Prussia, PA 19406, USA. **E-mail:** steven.j.pascoe@gsk.com

Keywords: Chronic obstructive pulmonary disease, inhaled corticosteroid, fluticasone furoate, umecclidinium, vilanterol, long-acting muscarinic antagonist, long-acting β -agonist

Social media summary statement: Description of a landmark study designed to guide treatment choices between LABA/LAMA v ICS/LABA v ICS/LABA/LAMA in GOLD D subjects with COPD

ABSTRACT (Maximum 200 words)

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating with different inhaled combination therapies e.g. ICS/LABA, LABA/LAMA, ICS/LABA/LAMA, in this patient group are poorly understood, as is reflected in current guidelines. The InforMing the Pathway of COPD Treatment (IMPACT) study will evaluate the efficacy and safety of FF/UMEC/VI *versus* FF/VI or UMEC/VI over a 52-week treatment period. The study has been designed with a focus on understanding the comparative merits of each treatment modality in different phenotypes/endotypes.

This is a phase III, randomised, double-blind, three-arm, parallel-group, global multicentre study comparing the rate of moderate and severe exacerbations between FF/UMEC/VI and FF/VI or UMEC/VI over a 52-week treatment period. The study aims to recruit 10,000 patients from approximately 1070 centres. Eligible patients are aged ≥ 40 years, with symptomatic advanced COPD (GOLD group D) and an exacerbation in the previous 12 months.

The first patients were recruited to the IMPACT study (ClinicalTrials.gov: NCT02164513) in June 2014 and the anticipated completion date is July 2017.

Introduction

Chronic obstructive pulmonary disease (COPD) is known to be the fourth leading cause of death worldwide [1, 2]. The economic burden of COPD in the USA alone is approximately \$53.7 billion/year, with COPD exacerbations and severe COPD accounting for up to 84% of these costs [3].

COPD is characterised by chronic airflow limitation, resulting in progressively worsening symptoms, decreased activity, poor quality of life (QoL), exacerbations and premature death. Inhaled pharmacological maintenance therapy of chronic stable disease is largely limited to three classes of drugs: the long- and ultra-long acting anti-muscarinic and β_2 -agonist bronchodilators and inhaled corticosteroids (ICSs) [4]. The recent Global initiative for chronic Obstructive Lung Disease (GOLD) 2015 strategy document has suggested considering treatment options on a two-axis continuum based on exacerbation risk and symptomatic progression [5]. The suggested pharmacological treatment paradigm is one of incremental additions of therapy depending on disease severity and progression. There is currently a paucity of randomised, controlled trial data supporting the various pharmacological treatment options available [3, 6], with the exception of the addition of ICSs [7] and oral phosphodiesterase type 4 (PDE4) inhibitors [8] for those at risk of exacerbations. Furthermore, there is no suggestion that targeting therapy towards any particular disease endotype improves outcomes, largely based on the absence of robust clinical information to date. However, large observational studies such as ECLIPSE^{®1} (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) [9] and COPDGene[®] [10] are providing mounting evidence to help distinguish varying COPD phenotypes and potential markers of outcome, depending upon the underlying COPD biology. It appears that not all acute exacerbations are manifestations of the same pathobiological processes and there is compelling evidence to divide them into infective and eosinophilic; episodes manifesting both pathologies are relatively rare [11]. There are now data to suggest that eosinophilic events are more responsive to corticosteroids, whereas this treatment may be detrimental in the

¹ ECLIPSE[®] is a trademark of the GSK group of companies.

events of infective origin. In addition, compelling data from recent post-hoc analyses suggest that the reduction in exacerbation frequency seen with ICS treatment is directly related to the blood eosinophil count; there is **reduced** evidence of efficacy in patients with a count below $0.15 \times 10^9/L$ [12,13]. While ICSs decrease the risk of exacerbation in patients with COPD, they have been recognised as increasing the risk of pneumonia in GOLD D patients [14]. The risk of pneumonia may be **increased further** in patients with a low blood eosinophil count [15,16]. Whether blood eosinophil count can be used to stratify patients so as to minimise the risk of pneumonia and maximise benefit is an important area for further study.

It is estimated that almost 50% of patients who are administered with a long-acting inhaled drug receive an “open triple” ICS/long-acting muscarinic antagonists (LAMA)/long-acting β_2 -agonist (LABA) delivered via multiple inhalers [17–19]. Significant evidence exists to support the benefits to both lung function and symptoms of combining two bronchodilators. However, data for the positive effect on exacerbation prevention are limited to two large studies: the SPARK study, which was designed to examine this question [20], and the UPLIFT study, in which only 60% of patients received a LABA prior to randomisation to tiotropium [17]. There have been no prospective, randomised, controlled studies completed to date examining the benefits of dual bronchodilation (LAMA/LABA combinations) compared with ICS/LABA on exacerbations within an exacerbation-prone population. However, multiple recent studies with umeclidinium (UMEC), a LAMA, in addition to various ICS/LABAs, and similar studies with tiotropium and other LAMAs, have consistently shown benefit to lung function over and above the dual combination alone, similar to the effect size observed when adding a LAMA to a LABA monotherapy [21–23]. Extensive observational studies have suggested that triple therapy is effective in preventing exacerbations compared with dual therapy [24], which would seem to suggest that a net positive effect on exacerbations will be seen with triple therapy. There are robust data supporting the value of adding ICS therapy to LABA in preventing exacerbations [25, 26], but there are no randomised studies addressing the key question of whether or not ICS added

to dual bronchodilation is likely to offer additional protection. Importantly, no prospective studies have assessed the endotypes in which ICS add-on therapy would have the best therapeutic index.

Rationale

Since the recent widespread regulatory approval of fluticasone furoate (FF)/vilanterol (VI), UMEC/VI and UMEC monotherapy, it has proven possible to formulate all three agents within one device [27], raising the possibility of benefits for adherence levels and ease of switching between different classes and combinations (without changing the delivery device). However, for regulatory scrutiny and to further define the value of triple therapy, it is necessary to provide evidence from a prospective study to answer some of these key questions. We have, therefore, designed a large clinical study, IMPACT, to address these issues.

IMPACT is a phase III, randomised, double-blind, three-arm, parallel-group, global multicentre study designed to prospectively assess the benefits and risks of the closed triple FF/UMEC/VI therapy versus the treatment options of UMEC/VI and FF/VI dual therapies in symptomatic patients with COPD and a history of exacerbations, ~~with stratification by baseline blood eosinophil count.~~

Methods

Study design and participants

This ~~is a superiority study, which is designed to show the benefit of FF/UMEC/VI over FF/VI and UMEC/VI.~~ The study aims to randomise approximately 10,000 patients from approximately 1070 centres worldwide. The full study protocol is provided in the online supplementary appendix 1 and the study centres are listed in the online supplementary appendix 2.

The study will enrol symptomatic patients with COPD with a forced expiratory volume in 1 s (FEV₁) <50% of predicted and a history of one or more moderate or severe (hospitalised) exacerbations

within the previous year, or COPD with a FEV₁ of 50–80% of the predicted normal and two or more moderate or one severe (hospitalised) exacerbation in the previous year, in line with the GOLD D classification [4]. An overview of the key study inclusion and exclusion criteria is provided in table 1, including allowed and prohibited concomitant medications. The study has been designed to be as permissive as possible with regards to the inclusion of patients with significant cardiovascular disease in order to allow an assessment of safety that is more representative of the targeted population than often seen in clinical trials (*e.g.* patients with a past history of previous myocardial infarction [>6 months prior to screening] and New York Heart Association Class 1–3 heart failure are eligible, and QTc exclusion criteria have been relaxed, in contrast to the phase III studies on the individual assets and many other similar studies).

Ethical approval and patient consent

The study complies with the Declaration of Helsinki and good clinical practice standards from the International Conference on Harmonisation of technical requirements for the registration of pharmaceuticals for human use, and will be approved by institutional review boards/local ethics committees before study commencement. All patients will have provided written, informed consent before participating in the study.

This study will be guided by an Independent Data Monitoring Committee (IDMC), which will monitor the progress of the study and ensure that it meets ethics and patient safety standards. The IDMC comprises three people (an independent statistician, an independent respiratory clinician with experience in COPD and a cardiologist). Only the IDMC will be authorised to review un-blinded interim safety analyses during the trial, which will be performed and delivered to the IDMC by an independent Statistical Data Analysis Centre. In addition, a separate adjudication committee will be established to independently review and categorise the cause of each Serious Adverse Event (SAE) and death in the study. The committee members will remain blinded to treatment.

Randomisation and masking

The study will consist of a 2-week run-in period, a 52-week treatment phase and a 1-week safety follow-up phase. Patients will be randomised 2:2:1 to one of three treatment groups: FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg or UMEC/VI 62.5/25 µg, respectively, delivered via an identical ELLIPTA® dry powder inhaler. Patients will be randomised using the ~~validated~~ **proprietary** RANDALL software (GSK, Brentford, London, UK), and assigned to treatment using the Randomization and Medication Ordering System (RAMOS; GSK, Brentford, London, UK). Throughout the study, patients will attend seven or eight outpatient clinic visits (figure 1 and table 2): a screening visit, day 1 (randomisation), weeks 4, 16, 28, 40 and 52, plus follow up by telephone 1 week after completion of study treatment. Patients who permanently discontinue study treatment will be encouraged to continue in the study by participating in telephone contacts in order to assess exacerbations, SAEs and concomitant medications post-treatment.

Study endpoints

The study is designed primarily to address the impact on COPD exacerbations, which is reflected in the co-primary endpoints: the annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI and FF/VI. **As such, the primary hypothesis to be tested is, the addition of the triple combination therapy, FF/UMEC/VI will reduce moderate-to-severe acute exacerbations of COPD, compared with either FF/VI or UMEC/VI alone.** A number of ~~key~~ secondary endpoints will be assessed ~~to compare the benefits of triple therapy on~~ and the key ones are **changes in QoL and lung function. We have also defined, a priori, other secondary endpoints, as well as the corresponding definitions and analysis plans, including** incidence of pneumonia and cardiovascular events ~~will be evaluated~~ as safety endpoints ~~and. We will also examine~~ the relative magnitude of benefit of the three therapies on exacerbation prevention by baseline blood eosinophil count. ~~All~~ **A complete list of study endpoints are listed** is provided in table 3. Throughout the study,

each COPD exacerbation will be categorised based on severity, as mild, moderate or severe; the definitions of these categories are shown in table 4. Blood samples for eosinophil counts will be taken at the screening visit and at the randomisation visit. This will provide two baseline values, 2 weeks apart, to allow assessment of stability. Further blood samples for eosinophil counts will be taken at Weeks 16, 28 and 52, or when IP is discontinued.

Statistical analyses

~~This~~ For the primary analysis, this study has been designed to have 90% power to detect a 15% reduction in the annual rate of moderate and severe exacerbations with FF/UMEC/VI compared with UMEC/VI, and a 12% reduction compared with FF/VI. A total of 4000 patients will be randomised to receive FF/UMEC/VI, 4000 to receive FF/VI and 2000 to receive UMEC/VI. In addition, the study will have >90% power to detect a 20% reduction in moderate and severe exacerbations for FF/UMEC/VI compared with UMEC/VI, for the subset of patients that has eosinophils ≥ 150 cells/ μ L.

Sample size calculations assume that the ICS effect will be largely maintained and are based on previous studies, ~~which~~ Observed treatment benefits of approximately 20–30% when ICSs were added to LABA, compared with LABA monotherapy [7,28] powering at a 15% reduction allows for our estimate of the bottom end of the confidence for previously observed reductions. ~~and 10–12%~~ When using a dual bronchodilator, reductions of 10–12% have been observed compared with LAMA monotherapy [17,20], therefore, the study has been powered at the upper end of that estimate. For the purpose of sample size calculation, the exacerbation rate for FF/UMEC/VI in this study is estimated to be 0.80, based on a previously observed annual rate of 0.92 for on-treatment moderate and severe exacerbations in “high-risk” patients [5] who received FF/VI in two phase III studies (NCT01009463 and NCT01017952) [7].

Sample size calculations are based on a negative binomial model for exacerbation rate and use a two-sided 1% significance level in order to satisfy regulatory requirements for substantial evidence

of efficacy from a single study. The estimate of the dispersion parameter for the negative binomial model is 0.75, which is similar to that seen with fluticasone propionate/salmeterol in the Towards a Revolution in COPD Health (TORCH) study [29] and the dispersion in the FF/VI exacerbation program [7].

Blinded evaluation of exacerbation rates is planned for this study ~~for the purpose of sample size re-estimation~~ after one year of enrolment or when 5000 patients have been randomised, whichever occurs earlier. ~~This evaluation will allow for adjustment of the sample size in case the blinded exacerbation rate is found to be substantially greater than planned.~~ A subsequent evaluation will be done after approximately 18 months of enrolment or when 7500 patients have been randomised, whichever occurs earlier. Any subsequent change to the planned number of randomised patients will be documented in a protocol amendment.

The co-primary endpoints will be controlled for multiplicity using the truncated Hochberg method [30]. A two-sided 5% risk associated with incorrectly rejecting the null hypothesis (significance level) is considered acceptable for this study. The primary comparisons will be declared statistically significant if the p-value for both comparisons is significant at the 0.04 level. If the largest p-value for the two comparisons is above 0.04, the other comparison will be declared statistically significant if the smaller p-value is below 0.025. If at least one of the comparisons is significant, this will allow inference of secondary endpoints. The statistical hierarchy for all secondary endpoints is illustrated in figure 2.

The intent-to-treat (ITT) population will comprise all patients who are randomised to treatment and have received at least one dose of double-blind medication. This is the primary analysis population and will be used for safety and efficacy analyses. The pharmacokinetic (PK) study population will comprise of the subset of patients in the ITT population for whom a PK sample is obtained and analysed; this population will be used to assess all concentration-time and PK parameters.

Discussion

This is the first phase III randomised, double-blind, parallel-group study that will investigate the efficacy and safety of the “closed triple” FF/UMEC/VI therapy. It will assess the relative merits of three different inhaled pharmacological combinations in preventing exacerbations of COPD in symptomatic patients with advanced COPD and a history of exacerbation. Uncertainty lies around the additional benefit of triple therapy including an inhaled steroid over dual bronchodilation without ICSs. This study will address this and will have the power to prospectively answer key questions that may help to identify a more personalised approach towards the use of bronchodilators and ICSs in this patient population. Key secondary aims are to prospectively establish the relationship between blood eosinophils and the benefits of ICS therapy, and to evaluate the relationship between baseline bronchodilator reversibility and the benefits of bronchodilator therapy. Previous attempts have failed to show a consistent inpatient response and a correlation with outcomes that are not direct measures of airflow limitation (*e.g.* QoL, exacerbation frequency), likely due to methodological shortcomings. We have hypothesised that, by treating reversibility as a continuous variable and using a modelling approach, we will be able to more accurately describe that relationship.

Historically, the lung function benefit of ICS therapy in patients with more severe COPD has been described as small or modest (consistently shown to be approximately 50 mL) [7]. We will explore if this improvement in lung function in relation to ICS therapy is homogeneously spread over the entire population or unequally distributed. If the response is homogeneously spread we will determine if it is related to other benefits of ICS therapy, and whether or not it aligns with bronchodilator response to LAMA/LABAs and may modify the same bronchodilator response.

The size of the study will enable characterisation and an accurate evaluation of the impact of any excess pneumonia due to ICS therapy and may also help identify patients at higher risk of

pneumonia events. A low eosinophil count at presentation has been associated with pneumonia as one of the few independent markers of poor outcome [31]. However, it is unclear if this relates to a transient marrow suppression associated with acute infection or is linked to the severity of a chronic systemic disease. It has been previously suggested that low body mass index and low FEV₁ correlate with the risk of pneumonia and, therefore, the relative risk of excess pneumonia due to ICS therapy [32]. The IMPACT study is large enough to be able to prospectively address these issues.

The IMPACT study does have some limitations. There is the possibility of selection bias as the population is relatively adherent to medication, is able to read and patients with COPD due to exposures other than tobacco are excluded. There is also the possibility that some exacerbations may go unreported, additional data may not be collected due to limitations of the electronic diary and using medication count as a measure of adherence may be inaccurate. Furthermore, while a study duration of 52 weeks is generally accepted as being sufficient for assessing total exacerbations, it may not be enough to draw robust conclusions about severe exacerbations requiring hospitalization. These will need to be considered when the findings are interpreted.

The strengths of this study include a large, very well-characterised and less restrictive (from a safety perspective) population; the planned characterisation of all suspected pneumonias and moderate/severe COPD exacerbation with a confirmatory X-ray that is independently over-read; the use of an electronic diary to reliably capture symptoms on the day they occur; the provision to collect exacerbation and SAE data in patients who are permanently discontinued from study treatment; and the adjudication of all deaths and SAEs by an independent external adjudication committee.

Conclusion

The recent history of understanding the benefits of inhaled COPD therapy has mostly been driven by large randomised clinical trials such as EUROSCOP, ISOLDE, TORCH, UPLIFT, TIOSPIR, and SUMMIT

[33]. We believe that IMPACT is likely to be another highly important “landmark” study in this population of patients with COPD. It should answer key questions not only about the value of triple therapy compared to dual therapy, but also the relative comparative merits of the two dual therapies (ICS/LABA and LABA/LAMA) and the patient population that would benefit most. As well as prospectively addressing these key questions, we have no doubt that post-hoc analyses of the complete data set will generate many more hypotheses ready for testing in future studies. To that end, the individualised patient data will be put into the public domain for the scrutiny of others. More than anything, we are hopeful that this study will make a significant difference to how we understand the therapeutic index of these agents and combinations of agents, leading to improved outcomes for all COPD patients.

Acknowledgements

The authors wish to acknowledge the assistance of David A. Lomas (study design) and the following contributors who were GSK employees at the time of protocol finalization: Frank Barnhart (protocol preparation and study implementation), Niki Day, Ruby Birk, Michelle Fry, Irene Shupe, Nathalie Richard (all study feasibility and conduct), the late Ann Allen (PK), Maggie Tabberer, Kristina Yu-Isenberg (PRO design), and Sarah Landis (epidemiology input). Editorial support in the form of development of a draft outline, collation of comments and final manuscript submission was provided by Katherine St. John, PhD, of Gardiner-Caldwell Communications, Glasgow, UK, and Charlotte Kennerley, PhD, of Gardiner-Caldwell Communications, Macclesfield, UK, and was funded by GSK. This study is sponsored and funded by GSK (CTT116855).

Author contributions

S Pascoe, D Lipson, N Locantore, I Pavord, H Barnacle, N Brealey and R Mohindra contributed to the study design and drafting the study protocol. R Mohindra helped to operationalise the IDMC and

276 adjudication committees for this study. N Locantore and H Barnacle were involved in the data
277 collection. All authors assisted in the development of the manuscript.

278

279

References

1. Decramer M, Janssens W, Miravittles M. Chronic obstructive pulmonary disease. *Lancet* 2012; 379: 1341-1351.
2. WHO. Deaths from chronic respiratory diseases.
http://www.who.int/gho/ncd/mortality_morbidity/chronic_respiratory_diseases_text/en/.
Date last updated: 2015. Date last accessed: October 21, 2015.
3. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. *Chest* 2013; 143: 1444-1454.
4. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004; 23: 932–946.
5. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. <http://www.goldcopd.org/>. Date last updated: 2015. Date last accessed: October 21, 2015.
6. Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R. Triple therapy for the management of COPD: a review. *COPD* 2011; 8: 206-243.
7. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. *Lancet Respir Med* 2013; 1: 210-223.
8. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicenter randomized controlled trial. *Lancet* 2015; 385: 857-866.

9. Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Yates JC, Tal-Singer R, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. *Am J Respir Crit Care Med* 2014; 189: 1022-1030.
10. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010; 7: 32-43.
11. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Keadze T, Duvoix A, Lindblad K, Patel H, Rugman P, Dodson P, Jenkins M, Saunders M, Newbold P, Green RH, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE. Acute Exacerbations of COPD: Identification of Biological Clusters and Their Biomarkers. *Am J Respir Crit Care Med* 2011;184:662-71.
12. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med* 2015; 3: 435-442.
13. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 523-525.
14. Kew KM, Seniukovich A. Do inhaled steroids increase the risk of pneumonia in people with chronic pulmonary disease (COPD)? Cochrane Library.
http://www.cochrane.org/CD010115/AIRWAYS_do-inhaled-steroids-increase-the-risk-of-pneumonia-in-people-with-chronic-obstructive-pulmonary-disease-copd. Date last updated: 2015. Date last accessed: October 21, 2015.

15. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med*. 2015 ;3:435-42.
16. Barnes NC, Sharma R, Lettis S, Calverley PMA. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. *Eur Respir J* 2016 (in press).
17. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *New Engl J Med* 2008; 359: 1543-1554.
18. Wolters Kluwer's Source Lx Database. Hierarchical regimen analysis (HRA) application SLED report with filtering on patients aged 18+ with COPD only. Data from February 2011 through January 2012.
19. Wurst KE, Bushnell G, Shukla A, Muellerova H, Davis KJ. Factors associated with time to triple therapy in newly diagnosed COPD patients in the UK general practice research database. *Pharmacoepidemiol Drug Saf* 2013; 22(s1): 33(abstract 62).
20. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA 149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. *Lancet Respir Med* 2013; 1: 199-209.
21. Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstiens N, Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. *Thorax* 2015; 70: 519-527.
22. Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone

- propionate/salmeterol with tiotropium in COPD: a randomized controlled study. *Respir Med* 2012; 106: 382-389.
23. Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. *Respir Med* 2015; 109: 1155-1163.
24. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009; 180: 741-750.
25. Agusti A, Calverley PM, Decramer M, Stockley RA, Wedzicha JA. Prevention of exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. *J COPD Foundation* 2014; 1: 166-184.
26. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *Eur Respir J* 2003; 21: 74-81.
27. Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A. Pharmacokinetics of fluticasone furoate, umeclidinium and vilanterol as a triple therapy in healthy volunteers. *Int J Clin Pharmacol Ther* 2015; 53: 753-764.
28. Ferguson GT, Anzueto A, Fei A, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. *Respir Med* 2008; 102: 1099-1108.
29. Calverley PM, Anderson, JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *New Engl J Med* 2007; 356: 776-789.
30. Dmitrienko A, Tamhane A, Wiens B. General multistage gatekeeping procedures. *Biom J* 2008; 50: 667-677.

31. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012; 67: 970-976.
32. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. *Ann Am Thorac Soc* 2015; 12: 27-34.
33. Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. *Eur Respir J* 2013; 41: 1017–22.

TABLE 1 Key inclusion and exclusion criteria

Inclusion criteria		Key exclusion criteria
Demography		
Gender	Male or female	Women who are pregnant or are planning on becoming pregnant
Age at visit 1	≥40	<40
years	Outpatient	Inpatient
Status		
Consent and compliance	Written informed consent prior to study participation	Patients at risk of non-compliance or unable to follow study procedures
COPD		
Diagnosis	An established clinical history of COPD [4]	α1-antitrypsin deficiency as the underlying cause of COPD
Severity	A post-ALB/SAL FEV ₁ /FVC ratio of <0.70 at screening	Patients either:
Exacerbation history	Patients must demonstrate either: A) a post-BD FEV ₁ <50% predicted normal and ≥1 moderate or severe COPD exacerbation in the prior year B) a post-BD 50% ≤ FEV ₁ < 80% predicted normal and ≥2 moderate exacerbations or ≥1 severe COPD exacerbation (hospitalised) in the prior year	A) medically unable to withhold ALB/SAL for the 4-hour period required prior to spirometry testing at each study visit B) experiencing a moderate or severe COPD exacerbation that has not resolved ≤14 days prior to screening and ≤30 days following the last dose of any oral/systemic CS
Smoking history	Current or former [#] cigarette smokers [¶]	NA
Concomitant medications	Patients taking existing COPD maintenance treatment for ≥3 months prior to screening; all cardiovascular medications allowed	Incompatible medications (<i>e.g.</i> long-term antibiotic therapy); systemic, oral, or parenteral CS; an investigational drug or long-term oxygen therapy
Underlying conditions	NA	Including a current diagnosis of asthma, respiratory disorders (<i>e.g.</i> active tuberculosis, lung cancer, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases); pneumonia or other RTIs not resolved ≤14 days or ≤7 days, respectively, prior to screening

ALB/SAL: albuterol/salbutamol; BD: bronchodilator; COPD: chronic obstructive pulmonary disease; CS: corticosteroids; FEV₁=forced expiratory volume in 1 s; FVC: forced vital capacity; NA: not applicable; RTI: respiratory tract infection. [#]Previous smokers defined as those who have stopped smoking for ≥6 months prior to Visit 1. [†]Smokers with a history of smoking of ≥10 pack-years at screening.

TABLE 2 Time of patient visits to the clinic during the study and events planned during each visit

Protocol activity	Pre-screen	Screen	Treatment						Treatment discontinuation visit	Follow up Safety follow-up contact
	Visit 0	Visit 1 screen/run-in	Visit 2 randomisation	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7		
Study day		Week 2	Week 0	Week 4	Week 16	Week 28	Week 40	Week 52		1 Week follow-up
Window days		-3/+8		-4/+2	-8/+6	-8/+6	-8/+6	-8/+6		-1/+4
Procedures										
Written informed consent [#]	X	X								
Genetic informed consent [¶]	X	X								
Demography ⁺	X	X								
Medical history		X								
COPD and exacerbation history		X								
Concomitant medication assessment	X	X	X	X	X	X	X	X	X	X
Inclusion/exclusion criteria		X	X							
Smoking history		X								
Smoking status		X				X		X	X	
Smoking cessation counselling		X						X	X	
Register visit in RAMOS	X	X	X	X	X	X	X	X	X	X
Efficacy assessments										
Spirometry [§]		X	X [§]	X [§]	X [§]	X [§]	X [§]	X [§]	X [§]	

Reversibility testing [†]	X									
Diary/device training and registration	X	X								
Diary review		X	X	X	X	X	X	X		
Exacerbation assessment	X	X	X	X	X	X	X	X		X
SGRQ-C*		X	X			X		X	X	
BDI*		X								
TDI*			X			X		X	X	
CAT*	X	X	X			X		X	X	
EQ-5D-5L*		X				X		X	X	
Global rating of activity limitation*		X	X	X	X	X	X	X	X	
Global impression of change in activity limitation*			X	X	X	X	X	X		
Global rating of severity of COPD*		X								
Global impression of change in COPD*			X	X	X	X	X	X		
Healthcare resource utilisation			X	X	X	X	X	X		
Safety assessments										
Physical examination	X					X		X	X	
AEs assessment	X	X	X	X	X	X	X	X	X	X
Vital signs	X		X			X		X	X	
ECG	X		X			X		X	X	
Chest X-ray	X									
Oropharyngeal examination	X	X	X	X	X	X	X	X	X	
Pulse oximetry										
Laboratory assessments										
Haematology		X								

Haematology/ biochemistry	X		X	X		X	X
Urine pregnancy test	X	X	X	X	X	X	X
Hepatitis B and C tests	X						
Exploratory lab assessment							
Blood draw for fibrinogen			X				

AE: adverse event; ALB/SAL: albuterol/salbutamol; BD: bronchodilator; BDI: baseline dyspnoea index; CAT: COPD assessment test; COPD: chronic obstructive pulmonary disease; ECG: electrocardiogram; EQ-5D-5L: a standardised measure of health status developed by EuroQol; RAMOS: a GSK patient registration and reporting system; SGRQ-C: St George's respiratory questionnaire for COPD; TDI: transition dyspnoea index.

[#]Will be collected at the pre-screen visit, but may be collected at screening visit 1 if the patient has not taken any protocol-excluded medications.

[¶]Will be obtained at the same time as the study informed consent and must be obtained prior to obtaining a genetic blood sample.

⁺Will be captured at either the pre-screen visit or screening visit (for patients who do not have a pre-screen visit).

[§]At visits 2–7 (and the treatment discontinuation visit) both pre- and post-BD spirometry will be conducted. Pre-BD spirometry will be performed prior to taking morning dose of treatment, between 6am and 11am and after withholding rescue ALB/SAL for ≥4 hours. Post-BD spirometry will be conducted (prior to taking morning dose of treatment) ~10–30 mins after administering four puffs of ALB/SAL.

[†]Patients are required to withhold their usual morning doses of COPD medications including rescue ALB/SAL for the protocol designated period prior to reversibility testing.

^{*}Patient-reported assessments will be conducted in the following order and before other study assessments: SGRQ-C, BDI/TDI, EQ-5D-5L, CAT, global rating of activity limitation, global impression of change in activity limitation, global rating of severity of COPD and change in COPD. BDI/TDI will be conducted in a subset of patients at selected sites.

TABLE 3 Study endpoints

Secondary endpoints	Other efficacy endpoints	Safety assessments	Health outcomes assessments	PK endpoint
Change from baseline in trough FEV ₁ at Week 52 for FF/UMEC/VI <i>versus</i> FF/VI	Change from baseline in post-BD FEV ₁	Incidence of AEs	EQ-5D-5L score	Population PK data from a subset of ~300 patients
Change from baseline in SGRQ Total Score at Week 52 for FF/UMEC/VI <i>versus</i> FF/VI	Time to death from any cause	Incidence of pneumonia	Health care utilisation, including hospitalisation, emergency department and physician office/clinic visits	
Time to first on-treatment moderate or severe exacerbation comparing FF/UMEC/VI with UMEC/VI and with FF/VI	Responder rate based on SGRQ TS	Incidence of cardiovascular events (including supraventricular arrhythmia and non-fatal myocardial infarction)		
Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI in patients with a blood eosinophil count of ≥ 150 cells/ μ L	Annual rate of all on-treatment exacerbations (mild, moderate, severe)	ECG measurements		
Annual rate of on-treatment severe exacerbations comparing FF/UMEC/VI with UMEC/VI and with FF/VI	Annual rate of on-treatment moderate exacerbations	Vital signs		
	Time to first on-treatment COPD hospitalisation and COPD re-hospitalisation	Haematological and clinical chemistry parameters		
	Annual rate of exacerbations requiring systemic/oral CS	Oropharyngeal examinations		
	Annual rate of exacerbations requiring antibiotics	Incidence of bone fractures		
	TDI focal score comparing FF/UMEC/VI with FF/VI	Radiography		
	Use of rescue ALB/SAL (percentage of rescue-free days and occasions/day)	Physical examinations		
	Change from baseline in trough FEV ₁ at Week 52 comparing FF/UMEC/VI with UMEC/VI	Pulse oximetry		
		Urine pregnancy test (for women of child-bearing potential)		

Change from baseline in SGRQ TS
comparing FF/UMEC/VI with
UMEC/VI

Change from baseline and responder
rate for CAT™ score

Subject global rating of activity
limitation and subject global
impression of change in activity
limitation

Subject global rating of severity of
COPD and change in COPD

Annual rate of on-treatment severe
exacerbations comparing
FF/UMEC/VI with UMEC/VI in the
subset of patients with a blood
eosinophil count of ≥ 150 cells/ μ L.

AE: adverse event; ALB/SAL: albuterol/salbutamol; BD: bronchodilator; CAT™: COPD assessment test; COPD: chronic obstructive pulmonary disease; CS: corticosteroid; ECG: electrocardiogram; EQ-5D-5L: a standardised measure of health status developed by EuroQol; FEV₁: forced expiratory volume in 1 s; FF: fluticasone furoate; PK: pharmacokinetics; SGRQ: St George's respiratory questionnaire; TDI: transition dyspnoea index; TS: total score; UMEC: umeclidinium; VI=vilanterol.

TABLE 4 COPD severity category definitions

Severity	Definition
Mild	Worsening symptoms of COPD that are self-managed by the patient. Mild exacerbations are not associated with the use of corticosteroids or antibiotics.
Moderate	Worsening symptoms of COPD that require treatment with oral/systemic corticosteroids and /or antibiotics
Severe	Worsening symptoms of COPD that require treatment with in-patient hospitalisation

FIGURE 1 Study design. FF: fluticasone furoate; UMEC: umeclidinium; V: visit; VI: vilanterol.





FIGURE 2 Hierarchy of secondary endpoint analyses. COPD: chronic obstructive pulmonary disease; FEV₁: forced expiratory volume in 1 s; FF: fluticasone furoate; S1–4: secondary endpoints; SGRQ: St George’s respiratory questionnaire; UMEC: umecclidinium; VI: vilanterol.



Supplementary material

Appendix 1 – Study protocol and informed consent materials

Appendix 2 – Study centres (October 2015)

Country	Number of centres
Argentina	41
Australia	15
Austria	5
Belgium	15
Brazil	12
Canada	26
Chile	15
China	41
Columbia	7
Croatia	6
Czech Republic	15
Denmark	8
Finland	8
France	19
Germany	118
Hong Kong	5
Israel	12
Japan	108
Korea, Republic of	20
Netherlands	23
New Zealand	6
Norway	9
Peru	13
Philippines	9
Poland	6
Puerto Rico	5
Romania	8
Russian Federation	36
Singapore	4
South Africa	23
Spain	57
Sweden	10
Thailand	8

Turkey	5
Ukraine	10
United Kingdom	17
USA	290
Vietnam	7
